Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Amminger

Showing results (1-10 of 191) with videos related to

Pageof 20
Sort By:
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 14, 2011
Update on ω-3 polyunsaturated fatty acids in early-stage psychotic disordersG Paul Amminger, Patrick D McGorry
Evidence-Based Mental Health|March 6, 2012
Review: limited evidence from two small trials suggests no improvement in ASD symptoms with short term ω-3 supplementationG Paul Amminger, Miriam R Schäfer
JAMA Psychiatry|April 14, 2017
Negative Psychosis Prevention Trials-ReplyPatrick D McGorry, Barnaby Nelson, Paul Amminger
BMJ Case Reports|October 8, 2020
Treatment of social anxiety disorder and attenuated psychotic symptoms with cannabidiolMaximus Berger, Emily Li, Günter Paul Amminger
Frontiers in Psychiatry|October 30, 2018
Recent Meta-Analyses in the Clinical High Risk for Psychosis Population: Clinical Interpretation of Findings and Suggestions for Future ResearchBarnaby Nelson, Günter Paul Amminger, Patrick Denistoon McGorry
International Review of Psychiatry (Abingdon, England)|June 17, 2006
Bioactive lipids in schizophreniaGregor E Berger, Stefan Smesny, G Paul Amminger
Australian Journal of General Practice|July 31, 2022
Medicinal cannabis for the treatment of anxiety disordersMaximus Berger, G Paul Amminger, Iain S McGregor
Current Opinion in Psychiatry|May 3, 2011
Age of onset and timing of treatment for mental and substance use disorders: implications for preventive intervention strategies and models of carePatrick D McGorry, Rosemary Purcell, Sherilyn Goldstone, et al.
The Australian and New Zealand Journal of Psychiatry|May 11, 2023
The promise of the therapeutic use of cannabidiol for psychiatric disordersG Paul Amminger, Rebekah Street, Christopher G Davey, et al.
Archives of General Psychiatry|January 9, 2008
Back to the future: predicting and reshaping the course of psychotic disorderPatrick D McGorry, Alison R Yung, Andreas Bechdolf, et al.
Pageof 20

Showing results (1-10 of 191) with videos related to

Sort By:
Pageof 20
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 14, 2011
Update on ω-3 polyunsaturated fatty acids in early-stage psychotic disordersG Paul Amminger, Patrick D McGorry
Evidence-Based Mental Health|March 6, 2012
Review: limited evidence from two small trials suggests no improvement in ASD symptoms with short term ω-3 supplementationG Paul Amminger, Miriam R Schäfer
JAMA Psychiatry|April 14, 2017
Negative Psychosis Prevention Trials-ReplyPatrick D McGorry, Barnaby Nelson, Paul Amminger
BMJ Case Reports|October 8, 2020
Treatment of social anxiety disorder and attenuated psychotic symptoms with cannabidiolMaximus Berger, Emily Li, Günter Paul Amminger
Frontiers in Psychiatry|October 30, 2018
Recent Meta-Analyses in the Clinical High Risk for Psychosis Population: Clinical Interpretation of Findings and Suggestions for Future ResearchBarnaby Nelson, Günter Paul Amminger, Patrick Denistoon McGorry
International Review of Psychiatry (Abingdon, England)|June 17, 2006
Bioactive lipids in schizophreniaGregor E Berger, Stefan Smesny, G Paul Amminger
Australian Journal of General Practice|July 31, 2022
Medicinal cannabis for the treatment of anxiety disordersMaximus Berger, G Paul Amminger, Iain S McGregor
Current Opinion in Psychiatry|May 3, 2011
Age of onset and timing of treatment for mental and substance use disorders: implications for preventive intervention strategies and models of carePatrick D McGorry, Rosemary Purcell, Sherilyn Goldstone, et al.
The Australian and New Zealand Journal of Psychiatry|May 11, 2023
The promise of the therapeutic use of cannabidiol for psychiatric disordersG Paul Amminger, Rebekah Street, Christopher G Davey, et al.
Archives of General Psychiatry|January 9, 2008
Back to the future: predicting and reshaping the course of psychotic disorderPatrick D McGorry, Alison R Yung, Andreas Bechdolf, et al.
Pageof 20